Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Dr Lalchandani Labs Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹6.82 |
|---|---|
| Day's Range | ₹6.82 - ₹7.39 |
| Open | ₹7.00 |
| 52 Week Range | ₹06.46 - ₹21.22 |
| Volume | 64,000 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 4.36 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 98.30 |
| TTM EPS (₹) | 0.07 |
| P/E Ratio | 10.61 |
| Book Value(₹) | 0.43 |
| PAT Margin (%) | 9.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 3.61 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 44.54 |
| Expenses | N/A | N/A |
| PBT | N/A | 4.02 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 4.17 |
About Dr Lalchandani Labs Ltd.
| Founded | 2011 |
|---|---|
| Managing Director | Arjan Lalchandani |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,67,630.39 | 1,952.75 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,18,971.76 | 8,275.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,358.16 | 4,915.50 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,29,125.81 | 8,921.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,915.99 | 1,460.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,241.63 | 1,120.70 | 835.50 - 835.50 |
| Lupin Ltd. | 1,07,907.43 | 2,275.00 | 1,875.00 - 1,875.00 |
| Max Healthcare Institute Ltd. | 1,04,432.24 | 1,070.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,00,729.72 | 2,438.00 | 1,909.70 - 1,909.70 |
| Laurus Labs Ltd. | 1,00,227.92 | 1,866.00 | 810.05 - 810.05 |
No Records Found
Latest News
Aug
10
2026
Posted on Aug 10th 2026
Artemis Medicare Services submits analyst meet intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Artemis Medicare Services has informed about the proposed schedule of ‘Investor Conference’ in which the representatives of the Company will be participating on Thursday, August 13, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
10
2026
Posted on Aug 10th 2026
Global Longlife Hospital and Research informs about SAST
Global Longlife Hospital and Research has informed that it enclosed disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhruv Sureshkumar Jani.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
10
2026
Posted on Aug 10th 2026
Syschem India informs about clarification
Syschem India has informed that due to an inadvertent typographical error, “Q2 (Quarter-2)” has been mentioned at certain places in the Investor Presentation, whereas the same should have been mentioned as ‘Ql (Quarter-1)’, pertaining to the First Quarter of Financial Year 2026-27. Accordingly, wherever ‘Q2 (Quarter-2)’ appears in the said Investor Presentation, the same shall be read and understood as ‘Q1 (Quarter-1)’. Further clarified that the aforesaid error is purely typographical in nature and does not have any impact on the financial figures, operational information, financial results, or any other disclosures contained in the Investor Presentation. The Company regrets the inadvertent typographical error and is taking necessary steps to upload the corrected Investor Presentation on the Stock Exchange portal.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
9
2026
Posted on Aug 9th 2026
Par Drugs & Chem. - Quaterly Results
A fair growth of 20.10% in the revenue at Rs. 312.81 millions was reported in the June 2026 quarter as compared to Rs. 260.46 millions during year-ago period.A comparatively good net profit growth of 41.65% to Rs. 47.14 millions was reported for the quarter ended June 2026 compared to Rs. 33.28 millions of previous same quarter.Operating profit surged to 73.16 millions from the corresponding previous quarter of 53.98 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 312.81 | 260.46 | 20.10 | 312.81 | 260.46 | 20.10 | 1036.56 | 1009.74 | 2.66 |
| Other Income | 9.35 | 18.37 | -49.10 | 9.35 | 18.37 | -49.10 | 40.01 | 21.50 | 86.09 |
| PBIDT | 73.16 | 53.98 | 35.53 | 73.16 | 53.98 | 35.53 | 211.31 | 216.51 | -2.40 |
| Interest | 0.21 | 0.16 | 31.25 | 0.21 | 0.16 | 31.25 | 1.27 | 0.82 | 54.88 |
| PBDT | 72.95 | 53.82 | 35.54 | 72.95 | 53.82 | 35.54 | 210.04 | 215.69 | -2.62 |
| Depreciation | 9.64 | 9.04 | 6.64 | 9.64 | 9.04 | 6.64 | 37.03 | 36.47 | 1.54 |
| PBT | 63.31 | 44.78 | 41.38 | 63.31 | 44.78 | 41.38 | 173.01 | 179.22 | -3.47 |
| TAX | 16.17 | 11.50 | 40.61 | 16.17 | 11.50 | 40.61 | 41.93 | 45.65 | -8.15 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.36 | 0.40 | -940.00 |
| PAT | 47.14 | 33.28 | 41.65 | 47.14 | 33.28 | 41.65 | 131.08 | 133.57 | -1.86 |
| Equity | 123.05 | 123.05 | 0.00 | 123.05 | 123.05 | 0.00 | 123.05 | 123.05 | 0.00 |
| PBIDTM(%) | 23.39 | 20.72 | 12.85 | 23.39 | 20.72 | 12.85 | 20.39 | 21.44 | -4.93 |
Read More
Aug
9
2026
Posted on Aug 9th 2026
Akums Drugs & Pharma - Quaterly Results
The Revenue for the quarter ended June 2026 of Rs. 3922.75 millions grew by 18.00 % from Rs. 3324.43 millions.The Net proft of the company remain more or less same to Rs. 448.39 millions from Rs. 448.67 millions ,decline by -0.06%.Operating profit for the quarter ended June 2026 rose to 746.07 millions as compared to 726.63 millions of corresponding quarter ended June 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 3922.75 | 3324.43 | 18.00 | 3922.75 | 3324.43 | 18.00 | 13487.36 | 13117.84 | 2.82 |
| Other Income | 261.04 | 285.55 | -8.58 | 261.04 | 285.55 | -8.58 | 1129.65 | 1241.92 | -9.04 |
| PBIDT | 746.07 | 726.63 | 2.68 | 746.07 | 726.63 | 2.68 | 2104.25 | 2626.91 | -19.90 |
| Interest | 24.76 | 29.11 | -14.94 | 24.76 | 29.11 | -14.94 | 100.38 | 153.09 | -34.43 |
| PBDT | 721.31 | 697.52 | 3.41 | 721.31 | 697.52 | 3.41 | 1938.68 | 2473.82 | -21.63 |
| Depreciation | 127.95 | 102.46 | 24.88 | 127.95 | 102.46 | 24.88 | 455.03 | 395.45 | 15.07 |
| PBT | 593.36 | 595.06 | -0.29 | 593.36 | 595.06 | -0.29 | 1483.65 | 2078.37 | -28.61 |
| TAX | 144.97 | 146.39 | -0.97 | 144.97 | 146.39 | -0.97 | 367.25 | 468.39 | -21.59 |
| Deferred Tax | -8.53 | -15.84 | -46.15 | -8.53 | -15.84 | -46.15 | -3.69 | -7.14 | -48.32 |
| PAT | 448.39 | 448.67 | -0.06 | 448.39 | 448.67 | -0.06 | 1116.40 | 1609.98 | -30.66 |
| Equity | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 |
| PBIDTM(%) | 19.02 | 21.86 | -12.99 | 19.02 | 21.86 | -12.99 | 15.60 | 20.03 | -22.09 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr Lalchandani Labs Ltd. is ₹6.82 as of 2026-08-10.
The market capitalisation of Dr Lalchandani Labs Ltd. is ₹6.19 as of 2026-08-07.
The 1-year return of Dr Lalchandani Labs Ltd. is -7.35% as of 2025-08-04.
The P/E ratio of Dr Lalchandani Labs Ltd. is 10.61 as of 2026-08-10.
The 52-week high and low of Dr Lalchandani Labs Ltd. are ₹21.22 and ₹6.46, respectively, as of 2026-08-10.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
